METABOLIC & WEIGHT RESEARCH / FAQ
Direct Answers From the Literature
Citation-anchored responses to the questions readers bring most often to these three metabolic research peptides.
What does retatrutide do?
Retatrutide activates three metabolic receptors simultaneously: the GLP-1 receptor (suppresses appetite and slows gastric emptying), the GIP receptor (enhances glucose-dependent insulin secretion and modulates fat handling), and the glucagon receptor (increases energy expenditure and drives lipolysis). The combined effect produced a mean -24.2% body-weight change at 48 weeks versus -2.1% for placebo in a Phase 2 obesity trial of 338 adults [4]. It also reduced HbA1c by -2.02% in a type 2 diabetes trial [5] and reduced liver fat by -82.4% at 24 weeks in a metabolic liver disease substudy [3]. It is investigational and not currently approved.
How does retatrutide work?
Retatrutide is a single peptide molecule that binds and activates GLP-1R, GIPR, and GCGR in parallel. Cryo-EM structures resolved the binding to all three receptor complexes, with relative potencies approximately 8.9x native GIP at GIPR, 0.3x native glucagon at GCGR, and 0.4x GLP-1 at GLP-1R [2]. The glucagon-receptor arm adds energy expenditure and lipid mobilization on top of the appetite suppression and insulin sensitization from the GLP-1 and GIP arms — that additive thermogenic component is why retatrutide's weight-loss signal exceeds dual-agonist compounds [1]. Post-hoc metabolomics confirmed dose-dependent reductions in triglycerides and insulin-resistance biomarkers alongside the weight effect [7].
How to reconstitute retatrutide?
This desk does not advise on reconstitution, dosing, preparation, or administration of retatrutide or any other compound. Retatrutide is an investigational drug that has not been approved by any regulator; material available outside clinical trials is unverified research-grade material. The clinical trials used pre-filled, pharmaceutical-grade subcutaneous injection preparations formulated and supplied by the trial sponsor under Good Manufacturing Practice — a very different situation from research-chemical lyophilized powders available in the gray market. This site covers the published research record, not use guidance.
Is retatrutide FDA approved?
No. As of mid-2026, retatrutide is not approved by the FDA or any other regulatory agency. It is an investigational drug in Phase 3 clinical trials (the TRIUMPH program) run by Eli Lilly [4]. The FDA issued over 50 warning letters to vendors selling retatrutide for research or personal use in 2025, citing violations of the Federal Food, Drug, and Cosmetic Act [4]. Phase 3 data are expected to be submitted for regulatory review after trial completion; approval, if granted, would come after that review process.
What is tesamorelin?
Tesamorelin is a 44-amino-acid synthetic analogue of human growth hormone-releasing hormone (GHRH), modified at the N-terminus to resist enzymatic degradation in the bloodstream. It binds the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile endogenous GH secretion, which in turn drives IGF-1 production in the liver and visceral fat lipolysis [11]. It is FDA-approved as the first and only approved GHRH analogue (NDA 022505, 2010), with the specific indication of reducing excess abdominal fat in HIV-infected adults with antiretroviral-therapy-related lipodystrophy [9]. Outside that indication, all use is off-label.
What does tesamorelin do?
In HIV-associated lipodystrophy, tesamorelin significantly reduces visceral adipose tissue (mean -27.71 cm2 across five RCTs), trunk fat (-1.18 kg), and hepatic fat fraction (-4.28%), while increasing lean body mass (+1.42 kg), with no serious adverse events in the trial safety data [8]. A 2014 JAMA RCT found a -42 cm2 visceral fat treatment effect (P=0.005) and -2.9% hepatic lipid-to-water reduction (P=0.003) at 6 months in 50 HIV adults [10]. Outside the HIV lipodystrophy population, tesamorelin's effects have not been established by equivalent controlled trials.
How does tesamorelin work?
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade and stimulating pulsatile endogenous GH secretion. The released GH drives hepatic IGF-1 synthesis; GH and IGF-1 together promote lipolysis preferentially in visceral adipose tissue. Because tesamorelin amplifies the body's own GH rhythm rather than supplying exogenous GH, the pulsatile axis is preserved. In 13 healthy men given tesamorelin for two weeks, mean overnight GH increased (+0.5 ug/L) and IGF-1 rose by 181 ug/L (P<0.0001), without significant changes in glucose or insulin sensitivity [11].
Will tesamorelin help me lose belly fat?
This desk does not give medical advice or recommend any compound for any purpose. What the research shows: tesamorelin reduced visceral fat (mean -27.71 cm2) and trunk fat (-1.18 kg) in HIV-associated lipodystrophy trials [8]. That is a specific population with a specific fat-redistribution condition caused by antiretroviral therapy. For general visceral-fat reduction in people without HIV lipodystrophy, there are no equivalent large controlled trials. Additionally, visceral fat reaccumulates after discontinuation [12] — meaning any reduction is contingent on continued use. Individuals interested in the clinical evidence should discuss it with a licensed clinician.
What does the MOTS-c peptide do?
In cell and animal studies, MOTS-c activates AMPK — the cellular energy sensor — by inhibiting the folate cycle and de novo purine biosynthesis, raising AICAR which switches AMPK on. This shifts skeletal muscle cells toward increased glucose uptake and fat oxidation [15]. Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus and regulates antioxidant and metabolic gene expression via NRF2 [17]. In aged mice, exogenous MOTS-c significantly improved treadmill running capacity (P=0.000002), grip strength, and gait [16]. A 2024 study identified CK2 as a direct molecular target, with tissue-specific modulation as the mechanism for muscle metabolic effects [13]. All of this is preclinical; no human efficacy data exist.
What are the negative side effects of MOTS-c?
No human clinical trial data on MOTS-c adverse effects exist, so no human side-effect profile can be stated. The cautions in the published literature are: MOTS-c has no validated human pharmacokinetics (no measured half-life, bioavailability, or dose-response in humans); it is sold as unregulated research-chemical material with variable purity and identity; it is prohibited in elite sport; and a mitochondrial variant (m.1382A>C) is associated with altered glucose handling, suggesting genotype-dependent effects that are not uniform across individuals [15]. Community-circulated claims about side effects in humans are anecdotal and outside the peer-reviewed record covered here.
Is MOTS-c legal to buy?
MOTS-c is not FDA-approved for any use and is not a regulated pharmaceutical. In the United States, peptides sold for laboratory research are generally legal to purchase as research chemicals, provided the seller does not make drug claims. However, MOTS-c is prohibited in elite sport by WADA and anti-doping bodies such as USADA under hormone and metabolic modulator categories — athletes are subject to sanctions for use regardless of how it was obtained. Legal status for personal use varies by jurisdiction. This desk covers the research literature; readers should consult the regulations applicable in their own jurisdiction.
How often do you inject MOTS-c?
This desk does not provide dosing guidance, schedules, or administration advice for MOTS-c or any other compound. MOTS-c has no validated human pharmacokinetics and no published human dose-response data. Animal study protocols used intraperitoneal injection at doses in the range of 0.5-15 mg/kg/day — figures that cannot be extrapolated to human use [13][16]. There is no approved clinical protocol for MOTS-c in humans because no human clinical trials have been completed. Any circulating injection schedules are derived from animal protocols or community experimentation, neither of which constitutes clinical evidence.